Komatsu, Yoshito
Shimokawa, Tsuneo
Akiyoshi, Kohei
Karayama, Masato
Shimomura, Akihiko
Kawamoto, Yasuyuki
Yuki, Satoshi
Tambo, Yuichi
Kasahara, Kazuo
Article History
Received: 1 March 2022
Accepted: 8 July 2022
First Online: 6 August 2022
Declarations
:
: Institutional Review Boards approved the study protocol. This study was conducted in compliance with the ethical principles in the Declaration of Helsinki, the Pharmaceutical Affairs Law, the Ordinance for Enforcement of the Pharmaceutical Affairs Act, Ordinances Concerning GCP, International Council for Harmonisation GCP, Implementation of the GCP, Operation of Implementation Standards for Clinical Drug Studies, and all local regulatory requirements.
: All patients provided informed consent before initiating the study.
: Not applicable.
: Yoshito Komatsu has received research funding from Daiichi Sankyo, IQVIA Services Japan K.K., the National Cancer Center Japan, Astellas Pharma, Eisai, NanoCarrier, Mediscience Planning, Yakult Honsha, MSD, JFMC, Ono Pharmaceutical, Taiho Pharmaceutical, and Chugai Pharmaceutical; scholarship funding from Nippon Zoki Pharmaceutical, Nippon Kayaku, Asahi Kasei Pharma, Ono Pharmaceutical, Taiho Pharmaceutical, and Chugai Pharmaceutical; and payment or honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, Chugai Pharmaceutical, Bayer Yakuhin, Eli Lilly and Company, and Daiichi Sankyo. Akihiko Shimomura has received support for the present manuscript from Taiho Pharmaceutical; grants from Chugai Pharmaceutical, AstraZeneca, Daiichi Sankyo, and Eisai; and payment or honoraria from Chugai Pharmaceutical, AstraZeneca, Pfizer, Eli Lilly, Daiichi Sankyo, MSD, Eisai, and Novartis. Yasuyuki Kawamoto has received payment or honoraria from Eli Lilly Japan, Merck Biopharma, Taiho Pharmaceutical, Yakult Honsha, Ono Pharmaceutical, and Incyte Japan. Yuichi Tambo has received payment or honoraria from AstraZeneca, Chugai Pharmaceutical, Taiho Pharmaceutical, and MSD. Kazuo Kasahara has received consulting fees from Chugai Pharmaceutical, Taiho Pharmaceutical, Eli Lilly; payment or honoraria from MSD, AstraZeneca, Chugai Pharmaceutical, Bristol Myers Squib, Taiho Pharmaceutical, Pfizer, Eli Lilly, and Boehringer Ingelheim; holds patents with Boehringer Ingelheim; and serves on boards for AstraZeneca and Eli Lilly. Tsuneo Shimokawa, Kohei Akiyoshi, Masato Karayama and Satoshi Yuki have no conflicts of interest to declare.